Go to deals
Healthcare

Avacta Group has raised funds via a placing and subscription to both institutional and retail investors

Avacta Group Plc has raised US$60.3 million to continue developing next generation cancer therapies.

Avacta’s mission is to shape the future of medicine by developing safe and efficacious drugs and powerful research and diagnostic tools. Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumor-targeted chemotherapy. With this approach, the company aims to address the lack of a durable response to current immunotherapies experienced by most patients.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker, assisting Avacta’s management team and shareholders all the way from the start to the successful completion of the fundraising. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from both existing and new institutional investors, deal structuring, document preparation and the fundraise pricing and sizing.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Geoff  Nash

Geoff Nash

Partner

London, United Kingdom
Oaklins Cavendish

Related deals

Rotem Shani has completed an IPO
Real Estate

Rotem Shani has completed an IPO

Rotem Shani Ltd has completed an IPO to refinance and develop the company.

Learn more
Renita Medical has completed a fundraising round
Healthcare | TMT

Renita Medical has completed a fundraising round

Renita Medical Oy, a health tech company, has received an investment which provides it with resources to finalize their software development.

Learn more
Groupe Voie Lactée has been acquired by Initiative & Finance
Private Equity | Healthcare

Groupe Voie Lactée has been acquired by Initiative & Finance

JFC Industrie has sold Groupe Voie Lactée to Initiative & Finance.

Learn more